A Study Of PROMIS In Sarcoma Patients
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 25-010637
About this study
The purpose of this study is to investigate the Patient-Reported Outcome Measure Information System (PROMIS) and mobility in patients with sarcoma treated surgically using a novel smartphone application, ACTIVATION (Activity Capture To Investigate Voluntary Activity in Oncology and Normal populations).
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
All eligible patients will be seen by a musculoskeletal oncology surgeons at one of the participating sites.
All adult patients (≥18 years) diagnosed with bone sarcoma, soft tissue sarcoma, or giant cell tumor of bone undergoing operative tumor resection are eligible. The disease must be localized with no metastases at the time of diagnosis. Tumors can be primary or recurrent, and can be located in the pelvis, lower extremities, or upper extremities.
Patient must speak English and have an iPhone to be included in the study.
Exclusion Criteria:
Patients with metastatic bone disease, benign tumors, atypical lipomatous tumors, and dermatofibrosarcoma protuberans will be excluded.
Patients with metastases at the time of diagnosis will be excluded.
Pregnant patients and patients unwilling or unable to attend all follow-up evaluations will be excluded.
Lastly, patients with significant cognitive impairment or communication barriers that prevent informed consent and independent completion of study questionnaires will be excluded.
Note: Other protocol defined Inclusion/Exclusion Criteria may apply.
Eligibility last updated 9/16/2025. Questions regarding updates should be directed to the study team contact.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Rochester, Minn.
Mayo Clinic principal investigator Matthew Houdek, M.D. |
Contact us for the latest status |
|
More information
Publications
Publications are currently not available